Infectious Diseases News and Research

RSS

HIV and AIDS treatment: An interview with Charles Flexner, MD

The best estimates at the moment reckon that there are about 25 million people infected with HIV. Most of those are in resource-limited settings, including sub-Saharan Africa, South East Asia and India.

11 Jul 2012

Broken heart syndrome arms against epinephrine high

Takotsubo cardiomyopathy, or “broken heart syndrome,” may actually protect the heart from very high levels of epinephrine, suggest results from an animal study.

10 Jul 2012

Seizure risk should not influence AVM treatment decisions

Choosing to treat patients with arteriovenous malformations surgically rather than conservatively has no bearing on their risk for seizures, suggest findings from the Scottish Audit of Intracranial Vascular Malformations.

10 Jul 2012

Laparoscopic appendectomy preferable for obese patients

Obese patients with appendicitis have fewer postoperative complications, a shorter stay in hospital, and shorter operative times when treated with laparoscopic appendectomy rather than open appendectomy, study findings show.

10 Jul 2012

Alcohol has toxic effect on critical care services

Alcohol may account for more than one in 10 emergency department admissions, a study from the UK suggests.

10 Jul 2012

COPD still affects treatment received after heart attack

Patients with chronic obstructive pulmonary disease receive less aggressive treatment after hospitalization for acute myocardial infarction than those without the lung condition, US study results show.

10 Jul 2012

Scientists identify novel strategy to target Taspase1 enzyme

Scientists at the University Medical Center of Johannes Gutenberg University Mainz in Germany identified a novel strategy to target the oncologically relevant protein-cleaving enzyme Taspase1.

10 Jul 2012

UCLA to examine whether copper surfaces result in reduced hospital infection rates

Hospital-acquired infections are a huge public health burden, and hospital environments play a key role in harboring potentially deadly bacteria such as E. coli, C. difficile and methicillin-resistant Staphylococcus aureus.

10 Jul 2012

Inovio commences SynCon vaccine phase I study in H1N1 influenza

Inovio Pharmaceuticals, Inc. announced today that the first patients have been treated in a clinical trial evaluating immune responses in elderly adults immunized with Inovio's H1N1 SynCon universal influenza vaccine.

10 Jul 2012

Associated Press examines 'sense of optimism' in HIV fight as AIDS 2012 conference approaches

Noting more than 20,000 international HIV researchers and activists will gather in Washington, D.C., for the AIDS 2012 conference later this month, the Associated Press writes that there is "a sense of optimism not seen in many years -- hope that it finally may be possible to dramatically stem the spread of the AIDS virus."

10 Jul 2012

Einstein researchers to study molecular mechanism behind Ebola virus infection

The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine of Yeshiva University a five-year, $4.8 million grant to study the molecular mechanism that allows the Ebola virus to cause infection and spread in animals.

10 Jul 2012

Prediction tool indicates prognosis after cardiac arrest

US researchers report the development of a prediction tool that could help determine neurologic prognosis after in-hospital cardiac arrest.

9 Jul 2012

PCV13 offers best overall protection from CAP in young children

Researchers have identified a pneumococcal conjugate vaccine that is effective for treating bacteremic pneumococcal community-acquired pneumonia in children aged 5 years or younger.

9 Jul 2012

Regnite to treat primary restless legs syndrome launched in Japan

Astellas Pharma Inc. and XenoPort, Inc. announced today that Regnite (gabapentin enacarbil) Extended-Release Tablets will be launched in Japan on July 10, 2012. Regnite is approved in Japan for the treatment of moderate-to-severe primary restless legs syndrome (RLS).

9 Jul 2012

New hemoglobin monitoring system for anemia screening introduced by OrSense Ltd.

OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, introduced today at the 32nd International Congress of the International Society of Blood Transfusion (ISBT), in Cancun, Mexico, GlasswingTM, its next-generation, wireless, non-invasive hemoglobin (Hb) measurement system for anemia monitoring, hemorrhage detection and pre-donation screening.

9 Jul 2012

Treatment of Schizophrenia receives notice of intention to grant a European patent

BioLineRx (NASDAQ:BLRX)(TASE:BLRX), a biopharmaceutical development company, announced today that it has received from the European Patent Office a notice of intention to grant a European patent claiming the salt of BL-1020, a first-in-class orally available treatment for schizophrenia.

9 Jul 2012

OrSense launches Glasswing for anemia monitoring and hemorrhage detection

OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, introduced today at the 32nd International Congress of the International Society of Blood Transfusion (ISBT), in Cancun, Mexico, Glasswing, its next-generation, wireless, non-invasive hemoglobin (Hb) measurement system for anemia monitoring, hemorrhage detection and pre-donation screening.

9 Jul 2012

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.

9 Jul 2012

Merck, PDS Biotechnology enter licensing agreement for Versamune

PDS Biotechnology Corporation announced today that they have entered into an exclusive worldwide licensing agreement with Merck KGaA, Darmstadt, Germany, for use of PDS Biotechnology's novel Versamune nanotechnology platform in two of Merck's investigational antigen-specific cancer immunotherapies currently in pre-clinical development.

9 Jul 2012

UNN, UM establish firm foundation for mutual collaborations

A delegation from the University of Nigeria (UNN) has just completed a week in key laboratories and boardrooms at the University of Maryland's Baltimore campus exploring educational exchanges between the two universities.

8 Jul 2012